Literature DB >> 8282827

Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin.

K Matsumura1, A H Burghes, M Mora, F M Tomé, L Morandi, F Cornello, F Leturcq, M Jeanpierre, J C Kaplan, P Reinert.   

Abstract

The absence of dystrophin causes the drastic reduction of the dystrophin-associated proteins (DAPs) in the sarcolemma and the loss of the linkage between the subsarcolemmal cytoskeleton and the extracellular matrix in Duchenne muscular dystrophy (DMD) skeletal muscle. Here, we report a mild reduction of the DAPs in the unique Becker muscular dystrophy patients with huge deletions in the rod domain of dystrophin and a moderate reduction of the DAPs in patients with huge deletions that involve both the NH2-terminal and rod domains of dystrophin. The phenotype of the latter patients was more severe than that of the former. In both cases, however, the reduction in the DAPs was milder than in typical DMD patients or DMD patients lacking the COOH-terminal domains of dystrophin. Our results suggest that (a) the NH2-terminal and rod domains of dystrophin may not be essential for the interaction with the sarcolemmal glycoprotein complex; and (b) defects in the actin binding activity of dystrophin may cause disruption of the anchorage of the dystrophin-glycoprotein complex to the subsarcolemmal cytoskeleton, which may render muscle fibers susceptible to degeneration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282827      PMCID: PMC293741          DOI: 10.1172/JCI116989

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.

Authors:  S B England; L V Nicholson; M A Johnson; S M Forrest; D R Love; E E Zubrzycka-Gaarn; D E Bulman; J B Harris; K E Davies
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

2.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

3.  Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy.

Authors:  S B Malhotra; K A Hart; H J Klamut; N S Thomas; S E Bodrug; A H Burghes; M Bobrow; P S Harper; M W Thompson; P N Ray
Journal:  Science       Date:  1988-11-04       Impact factor: 47.728

4.  Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle.

Authors:  J M Ervasti; K Ohlendieck; S D Kahl; M G Gaver; K P Campbell
Journal:  Nature       Date:  1990-05-24       Impact factor: 49.962

5.  Purification of dystrophin from skeletal muscle.

Authors:  J M Ervasti; S D Kahl; K P Campbell
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

Review 6.  Deficiency of dystrophin-associated proteins: a common mechanism leading to muscle cell necrosis in severe childhood muscular dystrophies.

Authors:  K Matsumura; K P Campbell
Journal:  Neuromuscul Disord       Date:  1993-03       Impact factor: 4.296

7.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein.

Authors:  M Koenig; A P Monaco; L M Kunkel
Journal:  Cell       Date:  1988-04-22       Impact factor: 41.582

8.  Association of dystrophin and an integral membrane glycoprotein.

Authors:  K P Campbell; S D Kahl
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

9.  Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification.

Authors:  J S Chamberlain; R A Gibbs; J E Ranier; P N Nguyen; C T Caskey
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

10.  Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma.

Authors:  K Ohlendieck; J M Ervasti; J B Snook; K P Campbell
Journal:  J Cell Biol       Date:  1991-01       Impact factor: 10.539

View more
  15 in total

1.  Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design.

Authors:  Ava Yun Lin; Ewa Prochniewicz; Davin M Henderson; Bin Li; James M Ervasti; David D Thomas
Journal:  J Mol Biol       Date:  2012-04-11       Impact factor: 5.469

2.  Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.

Authors:  Sarah Forrest; Penny L Meloni; Francesco Muntoni; Jihee Kim; Sue Fletcher; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2010-12       Impact factor: 4.296

3.  Dystrophin: the long and short of it.

Authors:  R G Worton
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

Review 4.  Increasing complexity of the dystrophin-associated protein complex.

Authors:  J M Tinsley; D J Blake; R A Zuellig; K E Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

5.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

Review 6.  Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.

Authors:  Sasha Bogdanovich; Kelly J Perkins; Thomas O B Krag; Tejvir S Khurana
Journal:  J Mol Med (Berl)       Date:  2003-12-12       Impact factor: 4.599

7.  Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: mechanisms of dystrophin production.

Authors:  A V Winnard; J R Mendell; T W Prior; J Florence; A H Burghes
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

8.  CUGC for Duchenne muscular dystrophy (DMD).

Authors:  David J Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-01-12       Impact factor: 4.246

9.  Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther Clin Dev       Date:  2016-03       Impact factor: 5.032

Review 10.  Emerging strategies for cell and gene therapy of the muscular dystrophies.

Authors:  Lindsey A Muir; Jeffrey S Chamberlain
Journal:  Expert Rev Mol Med       Date:  2009-06-25       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.